A 78-year-old man developed *Cytomegalovirus* (CMV) colitis following treatment with prednisolone, and Epstein-Barr virus infection (EBV) reactivation-associated lymphoid interstitial pneumonia (LIP) following treatment with azathioprine, infliximab and prednisolone for active Crohn\'s disease \[*not all dosages and routes stated; duration of treatments to reaction onsets not stated*\].

The man was admitted due to progressive dyspnoea, fever and dry cough since few weeks, and acute confusion since 1 day. Two years prior to the admission, he was diagnosed with Crohn\'s disease and had received prednisolone \[*initial dosage not stated*\], azathioprine and mesalazine. Later, prednisolone was continued at a tapered dose of 7.5mg to maintain clinical remission. Ten weeks before the admission, he was hospitalised due to haematochezia. His blood CMV viral load was 595 copies/mL. A diagnosis of CMV colitis secondary to prednisolone was made.

The man was treated with ganciclovir. One month before the admission, he again developed haematochezia. The pathological showed moderate chronic active ileitis despite CMV viral load suppression. He was diagnosed with active Crohn\'s disease, and started receiving infliximab, azathioprine 50mg and oral prednisolone 60 mg/day along with mesalazine. His medical history was significant for hypertension, dyslipidaemia and old ischaemic stroke. At current admission, he had bi-temporal throbbing headache with a sudden onset of altered mentation. A cranial CT scan showed diffuse brain atrophy with small intraventricular haemorrhage in occipital horns of lateral ventricles without evidence of obvious aneurysm. Lumbar puncture showed xanthochromic CSF with WBC count 9 cells/µL, RBC count 51 000 cells/µL, glucose 51 mg/dL and protein 48 mg/dL. PCR showed negative results for herpes simplex virus, varicella zoster virus and CMV. Chest X-ray demonstrated bilateral interstitial infiltrates. Complete blood count analysis showed Hb 8.4 g/dL, WBC count 3460 /µL (neutrophil 87.5%, lymphocyte 6.2% and monocyte 5.7%) and platelet count 138 000 /µL. A moderate polychromasia and microspherocytes were noted on peripheral blood smear with a strongly positive direct Coombs\' test, suggestive of autoimmune haemolytic anaemia. Blood CMV and EBV viral loads were 21 709 and 85 715 copies/mL, respectively. He had positive EBV viral capsid antigen (VCA) IgG, EBV nuclear antigen (EBNA) IgG and CMV VCA IgG in the serum along with negative EBV VCA IgM and CMV VCA IgM. Bone marrow aspiration and biopsy revealed hypocellularity, no abnormal cell infiltrates, and negative result for EBV-encoded RNA (EBER) *in situ* hybridisation. A diagnosis of CMV syndrome was assumed. He was treated with ganciclovir; however, his clinical condition worsened. He further developed acute respiratory failure leading to acute respiratory distress syndrome (ARDS) requiring ventilator support. A chest CT scan showed diffuse interstitial mixed with multifocal irregular consolidation infiltrates. Bronchoscopy and bronchoalveolar lavage revealed WBC 139 cells/µL (neutrophils 53%). Diffuse interstitial infiltrates with lymphocytes and plasma cells, without viral inclusion bodies were noted on pathology of transbronchial biopsy. His CMV immunohistochemistry was negative; however, EBER *in situ* hybridisation (ISH) revealed ten positive cells per total 100 lymphocytes. Two weeks after the ganciclovir therapy, his blood CMV viral load decreased to 214 copies/mL, and became undetectable, whereas EBV viral load was still 549 697 copies/mL. Hence, a final diagnosis of EBV reactivation-associated LIP secondary to immunosuppressive treatment was made. His immunosuppressive treatment comprising azathioprine, infliximab and prednisolone were stopped, and he was treated with aciclovir. However, he developed multiple hospital-acquired infections comprising *Pneumocystis jiroveci* pneumonia, pulmonary aspergillosis and multidrug-resistant bacteria infection \[*aetiologies unspecified*\]. After 5 weeks of the hospitalisation, he died due to the aforementioned hospital-acquired infections, acute respiratory failure and ARDS.
